Author

Jeffrey A. Klomp

Michigan State UniversityORCID 0000-0002-5243-6987Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:drug response / drug discovery· 3 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Channing J. DeriD· 4 shared Adrienne D. CoxiD· 3 shared Clint A. StalneckeriD· 3 shared Kirsten L. BryantiD· 3 shared Runying Y. YangiD· 3 shared Wen-Hsuan ChangiD· 3 shared Andrew M. WatersiD· 2 shared Elisa BaldelliiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Channing J. DerORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Concurrent AXL inhibition enhances RAS and ERK inhibitor efficacy in KRAS-mutant pancreatic and lung cancer

Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp, Tamara Isermann, Sina Loewe, Wen-Hsuan Chang, Andrew M. Waters, Sheila R. Nicewarner Peña, Elisa Baldelli, Cole P Martin, Teresa Börding, Runying Y. Yang, Craig M. Goodwin, Prson Gautam, Mariano Ponz‐Sarvisé, , Bjoern Papke

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

bioRxiv · Aug 11, 2026 · PreprintCancer Biology

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer

Wen-Hsuan Chang, Alec J. Vaughan, Addison G. Stamey, Mariana Mancini, Makiko Hayashi, Runying Y. Yang, Ryan N. Robb, Daniel Andrussier, Jeffrey A. Klomp, Andrew M. Waters, Antje Schaefer, Brian Matthew Wolpin, Kirsten L. Bryant, Adrienne D. Cox, Fernando Moreira Simabuco, , Channing J. Der

This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.

bioRxiv · Apr 21, 2026 · PreprintCancer Biology

Dordaviprone/ONC201 Activation of the ClpP Mitochondrial Protease Inhibits the Growth of KRAS-Mutant Pancreatic Cancer and Overcomes RAS Inhibitor Resistance

Kristina Drizyte‐Miller, Seamus E. Degan, Ryan D. Mouery, Amber M. Amparo, Brandon L. Mouery, Wen-Hsuan Chang, Runying Y. Yang, Sheila R. Nicewarner Peña, Elisa Baldelli, Jeffrey A. Klomp, Edwin J. Iwanowicz, Lee M. Graves, Emanuel F. Petricoin, Adrienne D. Cox, Clint A. Stalnecker, , Channing J. Der

This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.

bioRxiv · Dec 3, 2025 · PreprintCancer Biology

YAP signaling promotes resistance to MEK and AKT inhibition in NF1-related MPNSTs

Lauren E. McGee, Jamie L. Grit, Curt J. Essenburg, Sophia Agrusa, Elizabeth A. Tovar, Lisa Turner, Katelyn Becker, Jason Zbieg, Anwesha Dey, Jennifer E. Klomp, Jeffrey A. Klomp, Marie Adams, Ian Beddows, Emily Wolfrom, Zhen Fang Fu, , Matthew R. Steensma

This study identifies YAP signaling as a driver of resistance to MEK and AKT inhibitors in NF1-related MPNSTs using preclinical models and spatial transcriptomics.

bioRxiv · Jun 16, 2025 · PreprintCancer Biology

TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress

Jay Ramanlal Anand, Gaith N. Droby, Sayali Joseph, Urvi Patel, Xingyuan Zhang, Jeffrey A. Klomp, Channing J. Der, Jeremy E. Purvis, Samuel C Wolff, Jessica L. Bowser, Cyrus Vaziri

This study identifies TRIP13 as a key factor protecting KRAS-mutant pancreatic cancer cells from DNA replication stress and therapy-induced damage.

NAR Cancer · Jan 15, 2025Peer-reviewedCancer Biology